AJP - Renal Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 259: F793-F800, 1990;
0363-6127/90 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siragy, H. M.
Right arrow Articles by Carey, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siragy, H. M.
Right arrow Articles by Carey, R. M.

AJP - Renal Physiology, Vol 259, Issue 5 793-F800, Copyright © 1990 by American Physiological Society


ARTICLES

Evidence that dopamine-2 mechanisms control renal function

H. M. Siragy, R. A. Felder, N. L. Howell, R. L. Chevalier, M. J. Peach and R. M. Carey
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville 22908.

Dopamine is synthesized by the kidney, and dopamine-2 (DA2) receptors are present in the renal glomerulus. However, no role for DA2 receptors in the kidney has been defined. We investigated the possible role of DA2 receptors in control of renal function by intrarenal infusion of a highly specific DA2 antagonist YM-09151 (YM), in conscious uninephrectomized dogs (n = 5) in metabolic balance at Na intake 40 meq/day. YM infused at 0.01 pmol.kg-1.min-1 did not cause any changes in urinary flow rate or Na excretion. Administration of YM (infusions from 0.1 to 10.0 pmol.kg-1.min-1) caused a significant dose-dependent diuresis (F = 20.3; P less than 0.001) and natriuresis (F = 35.2; P less than 0.0001) and an increase in glomerular filtration rate (F = 45.4; P less than 0.0001), renal plasma flow (F = 209.3; P less than 0.0001), and filtration fraction (F = 11.2; P less than 0.0001). No significant changes in plasma renin activity, plasma aldosterone concentration, or mean arterial blood pressure occurred with any of the doses of YM infused into the renal artery. Coinfusion of LY-171555, a specific DA2 agonist, at a dose that itself did not affect renal function, completely abrogated the renal hemodynamic and excretory changes induced by YM. The data suggest that dopamine produced intrarenally may act at renal vascular and/or glomerular DA2 receptors to control renal function.


This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
T. Hussain and M. F. Lokhandwala
Renal Dopamine Receptors and Hypertension
Experimental Biology and Medicine, February 1, 2003; 228(2): 134 - 142.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. A. Ladines, C. Zeng, L. D. Asico, X. Sun, F. Pocchiari, C. Semeraro, J. Pisegna, S. Wank, I. Yamaguchi, G. M. Eisner, et al.
Impaired renal D1-like and D2-like dopamine receptor interaction in the spontaneously hypertensive rat
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2001; 281(4): R1071 - R1078.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
G. Luippold, S. Schneider, V. Vallon, H. Osswald, and B. Muhlbauer
Postglomerular vasoconstriction induced by dopamine D3 receptor activation in anesthetized rats
Am J Physiol Renal Physiol, April 1, 2000; 278(4): F570 - F575.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. A. Jose, L. D. Asico, G. M. Eisner, F. Pocchiari, C. Semeraro, and R. A. Felder
Effects of costimulation of dopamine D1- and D2-like receptors on renal function
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1998; 275(4): R986 - R994.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Hussain and M. F. Lokhandwala
Renal Dopamine Receptor Function in Hypertension
Hypertension, August 1, 1998; 32(2): 187 - 197.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Ozono, D. P. O'Connell, C. Vaughan, S. J. Botkin, S. F. Walk, R. A. Felder, and R. M. Carey
Expression of the Subtype 1A Dopamine Receptor in the Rat Heart
Hypertension, March 1, 1996; 27(3): 693 - 703.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online